Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.

Next Previous
Trial Profile

Phase II Study of Everolimus in Refractory Testicular Germ Cell Cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Germ cell cancer; Testicular cancer
  • Focus Therapeutic Use

Most Recent Events

  • 11 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
  • 02 Jun 2015 Primary endpoint has not been met. (Response rate), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
  • 02 Jun 2015 Results (n=15) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top